[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353585-105":59,"doc-detail-353585-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","bcar3-hypomethylation-as-a-potential-diagnostic-marker-for-thyroid-cancer-and-its-mechanism-via-promoting-emt-and-aktmtor-pathway","BCAR3 Hypomethylation as a Potential Diagnostic Marker for Thyroid Cancer and Its Mechanism via Promoting EMT and AKT/mTOR Pathway","","Background: BCAR3 has been implicated in various cancers, yet its role in thyroid cancer (TC) remains unclear. This study investigated BCAR3 methylation, its functional effects, and the underlying mechanisms in TC. Methods: BCAR3 methylation was measured by MALDI-TOF in 422 TC and 371 benign thyroid nodule samples. Expression was assessed by immunohistochemistry, qPCR, and Western blot, and functional assays followed BCAR3 knockdown; PI3K activation was used for rescue. Results: BCAR3 showed significant hypomethylation in TC, with CpG_6 most strongly linked to risk; patterns varied by TC subtype. Mechanistically, BCAR3 knockdown reduced AKT/mTOR phosphorylation and EMT marker shifts, suppressing proliferation, migration, and invasion. Conclusions: BCAR3 hypomethylation supports TC progression through AKT/mTOR activation and EMT, highlighting methylation as a diagnostic biomarker and BCAR3 as a therapeutic target.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/bcar3-hypomethylation-as-a-potential-diagnostic-marker-for-thyroid-cancer-and-its-mechanism-via-promoting-emt-and-aktmtor-pathway/353585/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/bcar3-hypomethylation-as-a-potential-diagnostic-marker-for-thyroid-cancer-and-its-mechanism-via-promoting-emt-and-aktmtor-pathway/353585.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of this study on BCAR3 in thyroid cancer?","Question",{"text":112,"@type":113},"To determine BCAR3 methylation status, its functional impact on thyroid cancer cells, and the mechanisms involved.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was BCAR3 methylation measured and in which samples?",{"text":117,"@type":113},"BCAR3 methylation was analyzed by MALDI-TOF mass spectrometry in 422 thyroid cancer samples and 371 benign thyroid nodule samples.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism did the study support for how BCAR3 influences thyroid cancer progression?",{"text":121,"@type":113},"BCAR3 hypomethylation promoted thyroid cancer proliferation, migration, and invasion by enhancing AKT/mTOR activation and driving epithelial–mesenchymal transition (EMT).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353585,1790194310,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Article  \nBCAR3 Hypomethylation as a Potential Diagnostic Marker for Thyroid Cancer and Its Mechanism via Promoting EMT and AKT/mTOR Pathway  \nWenkang Yu 1,2,†, Yizhu Mao 1,†, Yifei Yin 3, Jiacheng Yang 1, Yi Zhang 4, Xuandong Huang 3, Yifen Zhang 4, Chenxia Jiang 5 and Rongxi Yang 1, *  \nAcademic Editor: Fabio Monzani  \nReceived: 13 October 2025  \nRevised: 3 January 2026  \nAccepted: 8 January 2026  \nPublished: 15 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing 211166, China  \n2 Hongkou District Center for Disease Control and Prevention, Shanghai (Hongkou District Institute of Health Supervision, Shanghai), Shanghai 200434, China  \n3 Department of Thyroid and Breast Surgery, The Affiliated Huai’an Hospital of Xuzhou Medical University and The Second People’s Hospital of Huai’an, Huai’an 223002, China  \n4 Department of Pathology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China  \n5 Department of Pathology, Affiliated Hospital of Nantong University, Nantong 226001, China  \n* Correspondence: [rongxiyang@njmu.edu.cn](rongxiyang@njmu.edu.cn)  \n† These authors contributed equally to this work.  \nSimple Summary  \nDistinguishing malignant from benign thyroid nodules preoperatively remains a significant diagnostic challenge. This study investigated the role of a gene called BCAR3 in thyroid cancer. Using a large cohort of 793 clinical samples and cell experiments, we discovered that BCAR3 loses a specific regulatory mark (DNA methylation) in thyroid tumors, and we demonstrated that BCAR3 promotes tumor cell growth, migration, and invasion through the AKT/mTOR pathway and epithelial–mesenchymal transition. Therefore, measuring BCAR3 methylation has the potential to serve as a novel diagnostic biomarker, and BCAR3 itself represents a promising future therapeutic target for thyroid cancer.  \nAbstract  \nBackground: BCAR3 has been implicated in various cancers, yet its role in thyroid cancer (TC) remains unclear. This study aimed to investigate the methylation status, functional effects, and underlying mechanisms of BCAR3 in TC. Methods: BCAR3 methylation was analyzed using matrix-assisted laser desorption/ionization–time-of-flight (MALDI-TOF) mass spectrometry in 422 TC and 371 benign thyroid nodule samples. Expression levels were assessed via immunohistochemistry, qPCR, and Western blot. Functional assays including proliferation, migration, and invasion were performed after BCAR3 knockdown. Rescue experiments using a PI3K activator were conducted to examine pathway mechanisms. Results: BCAR3 was significantly hypomethylated in TC compared to benign tissues (p \u003C 0.001), with CpG_ 6 most strongly associated with TC risk (odds ratio, OR = 1.73, p \u003C 0.001) . Notably, BCAR3 hypomethylation was more pronounced in cases with larger tumor size and advanced disease stage. Furthermore, BCAR3 methylation showed differential patterns across TC subtypes, with medullary thyroid carcinoma exhibiting the lowest methylation levels. BCAR3 expression was upregulated in TC tissues and cell lines (p \u003C 0.05) . Mechanistically, BCAR3 knockdown reduced phosphorylation of AKT/mTOR and altered expression of epithelial-to-mesenchymal transition (EMT) marker, characterized by an increase in E-cadherin and decreases in Vimentin and N-cadherin, and consequently suppressed proliferation, migration, and invasion (p \u003C 0.05) . Rescue experiments with a PI3K activator showed a trend towards restoration of these effects, although not to the  \nlevel of the control groups. Conclusions: BCAR3 hypomethylation contributes to TC cells’proliferation, migration, and invasion by promoting AKT/mTOR activation and EMT. These findings highlight ","cbCaikwwS557QSKO","https://ap.wps.com/l/cbCaikwwS557QSKO","pdf",7853270,21,"English","# Simple Summary\n# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What was the main goal of this study on BCAR3 in thyroid cancer?\",\"answer\":\"To determine BCAR3 methylation status, its functional impact on thyroid cancer cells, and the mechanisms involved.\"},{\"question\":\"How was BCAR3 methylation measured and in which samples?\",\"answer\":\"BCAR3 methylation was analyzed by MALDI-TOF mass spectrometry in 422 thyroid cancer samples and 371 benign thyroid nodule samples.\"},{\"question\":\"What mechanism did the study support for how BCAR3 influences thyroid cancer progression?\",\"answer\":\"BCAR3 hypomethylation promoted thyroid cancer proliferation, migration, and invasion by enhancing AKT/mTOR activation and driving epithelial–mesenchymal transition (EMT).\"}]","BCAR3 Hypomethylation as a Potential Diagnostic Marker for Thyroid Cancer and Its Mechanism via Promoting EMT and AKT/mTOR Pathway | PDF",1790106170,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a015a9cf0b7cd408ea6cc7240c02932.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7dac51fe26aca2ad885e3baee085f8d2.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d6ab4f1e26dfe60ce4a8f3c57d64e13.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c368f7df231bf442dc40820b01af9ae.webp",980,1385]